A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Sponsor
Myeloid Therapeutics
Study ID
NCT06478693
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.

Key Dates

Start date
Jul 1, 2024
Status verified
Jan 2025
Primary completion
Dec 31, 2027
Completion
May 31, 2028

Study Design

Enrollment
70 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: MT-303
    Participants will receive MT-303 through intravenous infusion.
  • Experimental: MT-303 + Atezolizumab + Bevacizumab
    Participants will receive MT-303 in combination with Atezo/Bev through intravenous infusion.

Primary Outcome Measure

Type, incidence and severity of Adverse Events [ Time Frame: Up to 2 years from the last dose of Investigational Medicinal Product (IMP) ]

Central Contacts

Related Studies